Written Question·Department of Health and Social Care·UIN 28286

Givinostat

Tabled: 3 February 2025
Answered: 10 February 2025

Question

Martin Wrigley

Liberal DemocratNewton Abbot

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure access to Givinostat for families of children with Duchenne muscular dystrophy.

Answer

Karin Smyth
ITF Pharma UK, the United Kingdom marketing authorisation holder for givinostat, is providing access to givinostat through a type of compassionate use scheme called an Early Access Programme (EAP). Under the EAP, givinostat is free to both patients taking...

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 28286) →

Partner sites